10 Years On, Chinese Biopharma Firms Making Inroads In US Clinical Trials
Seeking Major Market For Innovative Assets
Led by BeiGene, 20 firms have placed their bets on Phase III clinical studies for innovative drugs in the US and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.
You may also be interested in...
Deal Snapshot: Akeso has already sought to secure FDA approval for its PD-1 inhibitor, but the agency has shown reluctance to approve drugs based on China-only data.
Large or small, Chinese biotechs are receiving the cold shoulder from some investors amid souring investment sentiment. HanBio, Frontier and InnoCare have all seen their fundraising efforts hampered to various degrees.
A clutch of Chinese biopharma firms, including I-Mab, Lepu and Clover, are having second thoughts on some of their clinical development programs to conserve cash amid a funding squeeze.